Why Your Formulation Strategy Is Your Retention Strategy

Retention is one of the most discussed metrics in beauty right now. Publications, investors, and founders all seem to be asking the same question: what makes a customer come back? The answers that surface most often involve marketing. Better email sequences. More personalized post-purchase flows. Loyalty programs with tiered rewards. Community building. Social proof at exactly the right moment in the customer journey.

These are real levers. But in our experience working with beauty brands at the manufacturing level, they rarely explain why the brands with the highest repeat purchase rates have them. The explanation usually sits somewhere else entirely — in the formula itself.

The first purchase can happen for many reasons. A compelling brand story. Strong packaging. A viral moment. A founder people trust. But the second purchase happens for one reason: the product worked. The skin improved. The texture was right. The formula behaved the same way it did when the customer first tried it. That second decision is made alone, at a bathroom sink or vanity, without a marketing team in the room. It is either earned or it isn't.

This is what retention data is actually measuring. And the brands that understand it early build their formulation strategy accordingly.

What the retention number is telling you

A low repeat purchase rate is treated, almost universally, as a marketing signal. The solution proposed is almost always more touchpoints — more follow-up emails, better review solicitation, a stronger subscription offer. Sometimes those interventions help. But they help most when the product was already working and the brand just failed to stay present. When the product itself underdelivered, no email sequence closes that gap.

The most honest diagnostic question a founder can ask about a struggling repeat purchase rate is not "where did we lose the customer in the funnel." It is "what did the customer experience when they actually used the product." And that experience is determined, in large part, before the product ever reaches them — during formulation, stability testing, and production quality control.

A formula that performs brilliantly in the development phase but drifts between batches creates an inconsistent customer experience. A formula with inadequate stability can change in texture, color, scent, or efficacy over a product's shelf life. A formula built primarily around cost targets rather than performance targets may deliver an acceptable first impression and not much after that. In each case, the customer who doesn't repurchase isn't making a statement about your marketing. They're making a statement about what happened when the product ran out and they thought about whether to replace it.

The formulation gap that marketing cannot close

There is a category of brands that invests heavily in acquisition and underinvests in formulation rigor — and the pattern is visible in their retention curves. They grow. They generate buzz. Their DTC numbers look promising in the first few months after launch. And then something stalls. The cohort analysis starts showing that customers are not coming back at the rates the business model assumed. The instinct is to fix the funnel. The problem is often upstream.

We call this the formulation gap, and it is worth naming clearly: the distance between what a formula promises and what it consistently delivers across batches, across time, and across the conditions it will actually face in a customer's home. Heat. Light. Repeated opening and closing. Shelf life at the back end of the distribution chain. The formula that performed in controlled conditions needs to perform in uncontrolled ones, reliably, or the customer experience begins to vary in ways the brand cannot see and cannot control.

Marketing can narrow the top of the funnel indefinitely. It cannot close a formulation gap. And the brands that try — investing more in acquisition to compensate for weak retention — are running a unit economics problem that compounds over time rather than resolving.

What consistency actually requires

Formulation consistency is not an accident of good intentions. It is the result of specific decisions made early in the product development process and maintained throughout manufacturing.

Stability testing. A formula that has not been properly stability-tested is a formula whose behavior over time is unknown. Accelerated stability testing exposes products to elevated temperature and humidity conditions to simulate long-term shelf life in a compressed timeframe. Real-time stability testing runs alongside. Both are standard expectations at any rigorous contract manufacturer, and both generate the data that tells a brand not just whether the product is safe to launch, but whether the product a customer opens on day one will still be the product they experience on day ninety.

Batch-to-batch quality control. A formula is a set of specifications. Every production run is an execution of those specifications under real manufacturing conditions, with real raw material variation, real equipment, and real human hands involved. QC protocols exist to verify that what came off the line matches what was developed in the lab — in appearance, in pH, in viscosity, in microbial load, in fill weight, and in any performance characteristic the brand has committed to. Without those protocols, batch variation becomes invisible until a customer notices it.

A performance-first formulation brief. The brief that goes into product development sets the ceiling for everything that follows. A brief organized around ingredient trends will produce a formula that sounds good. A brief organized around cost minimization will produce a formula that pencils out. A brief organized around what the product needs to do for the customer, consistently, across the full arc of how they will use it — that is the brief that produces formulas with retention built into them. The performance targets, the skin feel, the stability requirements, the market compatibility all need to be in the brief before the first formulation iteration, not discovered afterward.

The cost of addressing this after launch

There is an economic argument for getting formulation right before launch that is often underappreciated, because it requires projecting costs that haven't happened yet.

The cost of a well-specified formulation brief, proper stability testing, and rigorous QC protocols is real and visible. The cost of not doing those things is deferred and invisible — right up until it isn't. A reformulation after launch involves re-running stability testing, potentially re-filing regulatory documentation, managing existing inventory and supply chain timing, and communicating changes to retailers, distributors, or customers who may already have feedback about the original product. In some cases, it involves pulling existing stock. In nearly all cases, it is substantially more expensive than doing the work at the development stage.

The brands that treat formulation rigor as an upfront investment rather than an unnecessary delay tend to move faster, not slower, once they launch. The production run that follows a well-specified development process is predictable. The product that comes out of it performs consistently. The retention data that follows reflects that consistency. And the brand is not managing a reformulation on top of a growth phase.

What this means for your next formulation brief

If you are in active development, or preparing for a reformulation, the most useful reframe is to treat your formulation brief as a retention document. What specific results does this product need to deliver, and how will you measure them? What stability conditions does it need to survive? What does batch-to-batch consistency look like in quantifiable terms? What happens to the formula at the edges of its expected use conditions?

These are manufacturing and development questions, not marketing questions. But they are answered, or left unanswered, before your customer ever opens the box.

If you are evaluating an existing product and wondering why retention is lower than expected, the honest version of that audit includes a formulation review alongside a funnel review. Cohort data can tell you when customers stopped coming back. It cannot, on its own, tell you why. The answer to that question often lives in the production records, the stability file, and the original development brief.

How we approach this at Vaulabs

At Vaulabs, we work with beauty brands from the early stages of formulation through production and beyond. One of the things we see most clearly from that vantage point is the difference in outcomes between brands that approached development as a retention investment and brands that approached it as a time-to-market race.

Both types of brands launch. The difference shows up six, twelve, and eighteen months later in the cohort data — and in whether the founder is focused on growth or quietly managing a retention problem they weren't expecting.

Every formula we develop is built around what the product needs to do, what it needs to survive, and what needs to be verifiable at every production run. That means stability programs built in from the start, QC protocols tied to the specifications the brief established, and batch documentation that creates a consistent paper trail between what was developed and what was produced.

If you are planning a new product launch or a reformulation and want to understand how to structure the development process around long-term performance rather than speed to market, we are happy to have that conversation. You can reach us at info@vaulabs.com or book a call through our website.

Natalie Vaulin is the founder of Vaulabs, a clean beauty contract manufacturer based in Clearwater, Florida. Vaulabs works with beauty brands on custom formulation, stability testing, and FDA-registered, GMP-compliant manufacturing.